Features

What do employers want? We ask three execs for their secrets and their insights

What do employers want? We ask three execs for their secrets and their insights

They share their insights, secrets, worries, and everything else in between.

The industry's winning — and losing — job titles, based on salary

The industry's winning — and losing — job titles, based on salary

Hint: it pays to be an EVP.

Pharma marketing salaries veer off track, dropping 2.6% in 2016

Pharma marketing salaries veer off track, dropping 2.6% in 2016

By

Execs say that career prospects are better than ever. Yet data from MM&M's annual Career and Salary Survey reveals a decline in growth.

Sudler New York's John Marchese on the New Talent Pool

Sudler New York's John Marchese on the New Talent Pool

By

"It's easy to 'fill open positions,'" Marchese says. "We've banned that phrase. If you do that, you're just checking boxes on a list."

Diabetes marketers turn to big data, gaming to improve outcomes

Diabetes marketers turn to big data, gaming to improve outcomes

By

Diabetes is one of the most stubborn conditions to treat effectively. Drugmakers are turning to machine learning, online coaching, and gamification.

The co-pay card debate simmers, as payers push back

The co-pay card debate simmers, as payers push back

By

Will this payer pressure pose an existential threat to co-pay cards even though patients love them?

PBMs push forward toward outcomes-based pricing, despite challenges

PBMs push forward toward outcomes-based pricing, despite challenges

By

The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.

Healthcare marketers: Don't forget about the baby boomers

Healthcare marketers: Don't forget about the baby boomers

By

Baby boomers have taken to health tech with surprising ease, opening up a wealth of opportunities for marketers savvy enough to pursue them.

The CIO, reimagined for pharma

The CIO, reimagined for pharma

By

Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.

Leadership Exchange: Engaging the Millennial Doctor

Leadership Exchange: Engaging the Millennial Doctor

By

In partnership with inVentiv Health, MM&M found a millennial doctor to ask about her frustrations with the existing pharma marketing model to her willingness to text patients.

Telehealth: Improving the customer experience but still an unknown for pharma

Telehealth: Improving the customer experience but still an unknown for pharma

By

Although telehealth is still in its early stages, it's building momentum — with good reason.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

By

Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.

What do physicians think about biosimilars?

What do physicians think about biosimilars?

By

A SERMO poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?"

2016 Pharma Report: All the data in one place

2016 Pharma Report: All the data in one place

Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.

Post Pfizer, Allergan faces the future

Post Pfizer, Allergan faces the future

By

Mere days after the Pfizer deal collapsed, top Allergan executives had nary an air of regret about them.

Spending on drugs is up, but by how much?

Spending on drugs is up, but by how much?

By

Total medicine spending surged to $424.8 billion in 2015, representing an increase of 12.2%. Here's why that growth figure is closer to 2.9%.

MM&M's Hall of Femme: 16 women leaders who changed the industry

MM&M's Hall of Femme: 16 women leaders who changed the industry

The 16 women profiled here number among those who have bridged the gender gap in agencies, biopharma, and medtech.

MM&M's Hall of Femme: 20 women to watch

MM&M's Hall of Femme: 20 women to watch

The MM&M Women to Watch, part of our inaugural Hall of Femme, salutes 20 aspiring healthcare commercial and marketing execs distinguishing themselves.

When it comes to professional ads, print makes its comeback

When it comes to professional ads, print makes its comeback

By

Following print's best year since 2011, it's time to rewrite those journal-advertising obituaries. Medical-surgical print journal spending in 2015 was up 8.4% to $372 million.

Which brands spent the most on professional ads in 2015?

Which brands spent the most on professional ads in 2015?

By

Here are the brands and companies that advertised the most on professional ads in 2015.

Retaining talent: How pharma can compete with Google

Retaining talent: How pharma can compete with Google

By

As tech behemoths like Google are attempting to poach the best and brightest, executives from pharma companies and agencies share new retention tactics.

How to win an MM&M award: the do's and the don'ts

How to win an MM&M award: the do's and the don'ts

Tip: Don't charge your intern with assembling your entry. Read more from our checklists of do's and don'ts, and don't forget that entries are due April 11.

Healthcare industry seeks to reform its position as hacking target

Healthcare industry seeks to reform its position as hacking target

Given the value of its data and its relatively backward security measures, the healthcare industry has become a prime target for hackers. But industry experts say changes are afoot.

Pharma turns to mobile, population data to market to docs

Pharma turns to mobile, population data to market to docs

By

Discover why even digitally native physicians can no longer abide the flood of information e-sent their way.

Sensors, technology open the door to new era for clinical trials

Sensors, technology open the door to new era for clinical trials

By

Welcome to the mobile era for clinical trials, in which phone and tablet technology promise to upend a costly and unwieldy process.

Drugmakers partner in immuno-oncology, to better capture market share

Drugmakers partner in immuno-oncology, to better capture market share

By

Manufacturers team up to study drug combinations, a strategy expected to advance the category.

Celebrity pharma ads: Opportunity or PR disaster?

Celebrity pharma ads: Opportunity or PR disaster?

By

Tapping celebrities for brand or awareness campaigns ensures a high degree of attention, but such arrangements come with concerns that "regular" ones do not.

Medical Advertising Hall of Fame inductees of 2016

Medical Advertising Hall of Fame inductees of 2016

By

A pharma research forefather. An agency builder. A "guy you wanted in the room." These Medical Advertising Hall of Fame inductees are a professionally diverse and richly worthy trio.

Making the Case for the Value of Co-pay Cards

Making the Case for the Value of Co-pay Cards

Now that payers are locking in discounts at launch from drugmakers, where do co-pay cards fit in the marketing mix?

With PCSK9s, payers say, 'Let the market decide'

With PCSK9s, payers say, 'Let the market decide'

By

It's possible that payers won't prove the wild card in the PCSK9 derby. Instead, physician preference may do more to shape the market and maybe even force payers' hands.

 MM&M's Top 40 Healthcare Transformers of 2016

MM&M's Top 40 Healthcare Transformers of 2016

Here are the 40 executives, investors, entrepreneurs, designers and thinkers who are ushering the industry into its new technological golden era.

Leadership Exchange: Social Listening

Leadership Exchange: Social Listening

By

Social listening can help all along the value chain—from research and discovery to developing marketing plans and strategy.

Lack of expertise limits pharma's Facebook use

Lack of expertise limits pharma's Facebook use

By

With few exceptions, pharma brands haven't made much headway on Facebook. Marketers won't see real results until they cede control and stop chasing likes.

What pharma companies and agencies can learn from Amazon

What pharma companies and agencies can learn from Amazon

By

In the wake of an exposé on Amazon's corporate culture, pharma companies and agencies strive to keep employees as happy and satisfied as their clients.

Wearables have yet to move past the hype

Wearables have yet to move past the hype

By

Wearables has been the buzziest of healthcare-related buzzwords. And yet here we are in January 2016, still awaiting their iPhone moment.

Patient Marketing: Dissed Content?

Patient Marketing: Dissed Content?

By

Content marketing continues to strike fear into the hearts of pharma marketers. Doing it properly requires courage, commitment, creativity—and perhaps a little wiggle room to fail and learn.

Leadership Exchange: Launching at the Speed of Digital

Leadership Exchange: Launching at the Speed of Digital

By

It's no secret that speed matters in customer interface. Marc Iskowitz settles into the moderator's seat to find out how biopharma—an industry not known for moving with rapidity—is digitally shifting its commercial model into a higher gear

Data Management: Not If, But When

Data Management: Not If, But When

Healthcare may seem to have been unscarred by the ongoing rash of high-profile cyber-attacks, at least compared with retail and financial organizations. But to hear security pros tell it, the industry is increasingly finding itself as much of a target as companies in other sectors—if not more of one. Karen Epper Hoffman surveys the potential damage

Outlook 2016: High Science, High Stakes

Outlook 2016: High Science, High Stakes

By

The year 2015 may have lacked a ­hall-of-fame debut on par with 2014's hep.-C launches, but the year featured its share of intrigue in the form of sky-high valuations forcing big organizations to adjust their M&A approach and more. In this Q&A, Jon Gardner, deputy news editor at EvaluatePharma's EP Vantage, reads the tea leaves and hands out some awards—including Company of the Year honors for a controversial candidate

The Pipeline Report 2016: Big-Time Upside

The Pipeline Report 2016: Big-Time Upside

By

A peek at 159 aspiring agents, with profiles on 17 that could shoot to stardom. Rebecca Mayer Knutsen has the forecast

Outlook 2016: A Pharma Pile-On

Outlook 2016: A Pharma Pile-On

By

To hear politicians tell it—especially the ones seeking President Obama's job—pharma is motivated by profit and needs to be brought to heel. The reality of the situation, inside DC and out, is just a tad more complex. Larry Dobrow takes a closer look at what might be coming down the policy pipeline Illustration by Alex Fine

MM&M Awards 2015: The Gold Club

MM&M Awards 2015: The Gold Club

By

Pharma marketers of all stripes came together on October 1 in New York City to celebrate another outstanding year's worth of work—and play Photos: Dan D'Errico

Leadership Exchange: Transforming Patient Advocacy

Leadership Exchange: Transforming Patient Advocacy

It's an entirely different day for patient advocacy, yet we've only scratched the surface. Advocates and their pharma counterparts discuss what's standing in the way of deeper collaboration. Marc Iskowitz chairs a lively debate

Reel Marketing: Choose Your Own Adventure

Reel Marketing: Choose Your Own Adventure

To date, pharma marketers have viewed interactive video as more or less a curio—a tactic best assigned to next year's to-do list. But in doing so, they're missing a huge opportunity to connect in ways that more linear forms of advertising can't match. By way of IKEA and Coldplay, Mitch Apley explains

Engaging HCPs: Beer or Tacos?

Engaging HCPs: Beer or Tacos?

By

As pharma marketers continue on their age-old quest to engage physicians, the either/or choice between reps and digital tactics has largely gone away in favor of programs that incorporate both. At the same time, certain segments of the business are still finding their way in the brave new digital world. Larry Dobrow surveys the scene

The Programmatic Movement: A Programmatic Primer

The Programmatic Movement: A Programmatic Primer

By

Programmatic buying has started to take over the placement of digital ads, to the tune of $15 billion in 2015 sales. Is pharma in the process of following suit or will concerns about privacy and fraud dampen industry enthusiasm? Barbara Peck assesses the pros and cons

Leadership Exchange: Reconcilable Differences

Leadership Exchange: Reconcilable Differences

By

Get on a plane. Pick the right people. Use less e-mail. More SOPs. Marc Iskowitz asks seven execs from both sides of the agency-client divide how to partner despite rising challenges ALL PHOTOGRAPHS THROUGHOUT BY ERICA BERGER

Non-Personal Promotion: Pitchers of Records

Non-Personal Promotion: Pitchers of Records

For all the talk about EHRs and their eventual point-of-care ubiquity, skeptics remain. Will EHR platforms ever become penetrable enough for pharma to consider them as an integral part of the non-personal promotion tool kit? James Chase reports

Cloud Marketing: Faces in the Cloud

Cloud Marketing: Faces in the Cloud

As the need for more informed conversations with KOLs has grown, so too has the role of medical science liaisons. But as they attempt to bolster trust and familiarity with those audiences, MSLs are challenged by the volume of personalized information they need at their disposal to engage in a meaningful way. Enter—what else?—the cloud. Veeva Systems' Robert Groebel explains

Agency Culture: Firm Foundations

Agency Culture: Firm Foundations

By

Recruiting and retaining talent have always been concerns for healthcare agencies—and as the pace of industry has quickened, the challenge has intensified. James Chase assesses the opportunities and pain points—the methods and the madness—of agency careers / Illustration by A. E. Kieren

OPINION

Email Newsletters